StartUpMonday #32: Three Medical Marvel Startups You Won’t Hear About, but Should Know About
Let’s face it, medical research startups are most likely never going to make it to the level of fame that social networks such as Facebook and Twitter have reached. The sad but true fact is that there are some pretty amazing progressions going on out there in the medical world that the majority of us are simply unaware of. Make yourself familiar with these leading startups that are already on the pathway to saving millions of lives every year.
Award Winning Swiss Startup, ProteoMediX is Pioneering in the Cancer Detection Field
Founded in March 2010, ProteoMediX is a spin-off company of ETH Zurich specializing in non-invasive diagnostic assessments for the early identification of cancer and safer treatment thereafter. The company chose to initially focus on improving detection techniques for prostate cancer, which is often misdiagnosed or missed altogether by current tests implemented by healthcare professionals. ProteoMediX’s research led to the discovery of protein-based biomarkers which enabled their scientists to understand the complexity of cancer better, and therefore create techniques for more accurate detection at earlier stages. This breakthrough is exclusively owned by ProteoMediX, and has earned its fair share of awards, including The Swiss Technology Award 2012, The Life Sciences Prize 2012, and the W.A de Vigier Award 2012 (to name a few).
The Swiss based startup aims to significantly improve survival rates of cancer through a combination of early detection and correct prediction of the most compatible treatment. More than 10 million people worldwide die from cancer every year, making it the second biggest cause of mortality for the human species. With accurate and early detection however, the patient stands a much higher chance of survival and treatment costs are significantly reduced.
PharmPool to Save the US Economy $120bn a Year
Adverse reactions to prescribed drugs are the 4th biggest killer in the US today. 100,000 deaths, and over 2 million hospitalizations every year can be attributed to lethal doses or dangerous combinations of medication. According to the FDA, around $130 billion is spent on a yearly basis dealing with the side effects of incorrect drug taking. If 50%-70% of these cases can be prevented (as research has shown) why isn’t more being done to reduce these shocking statistics?
Thankfully, Israeli health care startup, PharmPool, has crafted a mobile application that aims to hand the power back to patients when it comes to their medication. The smart solution can identify when a particular drug therapy is not suited to a particular patient, taking into consideration their clinical background and other parameters via its unique algorithm. PharmPool will immediately identify and alert you of potential drug-drug clashes, drug disease concern, and vital drug information. Not only does the app help you avoid dangerous concoctions, it also functions as a personal drug management platform, helping to remind you to take the right pills at the right time.
PharmPool’s goal is to make drug therapies safer, reducing the number of adverse drug reactions, and with it, the costs involved for medical institutions. Founders Michael Kand, Yosi Karl, and Ariel Kahan are no newbies to the world of entrepreneurship, or the pharmaceutical industry, for that matter. As an experienced pharmacist, a software developer with over 30 years experience, and a mobile entrepreneur, they are a well prepared team for all the challenges that leading a medical startup can throw at you.
NBE Therapeutics – Frontrunner in the Development of ADC Drugs
As a pioneer and leader in the field of ADCs (Antibody Drug Conjugate) for cancer treatment, NBE Therapeutics is no ordinary startup company. After discovering “enzymatic, site-specific toxin-antibody conjugation technologies” (a mouthful, we know) the company now plans on using this to create a whole range of ADC drugs to successfully treat all different types of cancers at different stages.
NBE Therapeutics was founded in Switzerland in 2012 by biotech entrepreneur Dr. Ulf Grawunder and is privately owned. Financial supporters include the Boehringer Ingelheim Venture Fund and various private investors. As a prominent company in its field, staff at NBE Therapeutics make frequent appearances at the world’s biggest ADC events, including the ADC summit in London, the Antibodies in Drug Discovery Congress in Cambridge (UK), and the World ADC Summit Europe in Berlin.